CN Patent

CN107412230A — 一种5‑ht1f 受体激动剂的组合物

Assigned to Colucid Pharmaceuticals Inc · Expires 2017-12-01 · 8y expired

What this patent protects

本发明涉及一种5‑HT1F受体激动剂的组合物。更具体而言，本发明涉及2,4,6‑三氟‑N‑[6‑(1‑甲基‑哌啶‑4‑基羰基)‑吡啶‑2‑基]‑苯甲酰胺和药学上可接受的载体的药用组合物。

USPTO Abstract

本发明涉及一种5‑HT1F受体激动剂的组合物。更具体而言，本发明涉及2,4,6‑三氟‑N‑[6‑(1‑甲基‑哌啶‑4‑基羰基)‑吡啶‑2‑基]‑苯甲酰胺和药学上可接受的载体的药用组合物。

Drugs covered by this patent

lasmiditan-succinate (LASMIDITAN SUCCINATE)

Patent Metadata

Patent number: CN107412230A
Jurisdiction: CN
Classification: —
Expires: 2017-12-01
Drug substance claim: No
Drug product claim: No
Assignee: Colucid Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.